Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy
Preprint
- 31 October 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of thousands of tumor samples. Our analysis revealed that tumors with mutations in CRs are associated with high tumor mutational burden (TMB). The co-occurrence of mutations in multiple CRs was linked with a further increase in TMB. Given that TMB may predict the clinical response to immune checkpoint inhibitor (ICI) treatment, we investigated the relationship between mutations in CRs and ICI response. We found that patients harboring mutations in CRs exhibited improved responses to ICI treatment, comparable to those with deficiencies in canonical DNA repair pathways. Overall, this study uncovered significant relationships between mutations in chromatin regulators and critical features of cancer, underscoring the need for further functional and clinical studies.Keywords
All Related Versions
- Version 1, 2025-10-31, Research Square
- Published version: Clinical Epigenetics, 18 (1).
This publication has 23 references indexed in Scilit:
- Cancer epigenetics: from laboratory studies and clinical trials to precision medicineCell Death Discovery, 2024
- Landscape of somatic alterations in large-scale solid tumors from an Asian populationNature Communications, 2022
- Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patientsCell, 2022
- Pan-cancer analysis of whole genomesNature, 2020
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Epigenetic modulators, modifiers and mediators in cancer aetiology and progressionNature Reviews Genetics, 2016
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the hostNature Reviews Cancer, 2013
- Cancer Epigenetics: From Mechanism to TherapyCell, 2012
- Cancer epigenetics reaches mainstream oncologyNature Medicine, 2011